IVA.PA - Inventiva S.A.

Paris - Paris Delayed Price. Currency in EUR
2.0300
-0.0100 (-0.49%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close2.0400
Open2.0900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.0200 - 2.0900
52 Week Range1.5400 - 8.8000
Volume12,709
Avg. Volume41,997
Market Cap45.368M
Beta (3Y Monthly)0.24
PE Ratio (TTM)N/A
EPS (TTM)-1.6370
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.14
  • GlobeNewswire

    Inventiva announces the positive recommendation of the 4th and last DSMB of the Phase IIb clinical study with lanifibranor in NASH

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the positive recommendation of the fourth and last Data Safety Monitoring Board (DSMB) of the NATIVE Phase IIb clinical study evaluating lanifibranor in NASH. No safety issues were reported and, as for the first three DSMB meetings, the DSMB recommended to continue the study without changing the protocol.

  • GlobeNewswire

    Inventiva achieves a major milestone by completing patient recruitment for its Phase IIb clinical study with lanifibranor in NASH

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the successful completion of patient recruitment for its Phase IIb NATIVE (NASH Trial to Validate IVA337 Efficacy) clinical trial evaluating lanifibranor, the Company’s lead product candidate, for the treatment of non-alcoholic steatohepatitis (NASH). A total of 247 patients have been randomized in the Phase IIb NATIVE trial, exceeding the initial target of 225 patients following an acceleration of inclusions over the last months.

  • GlobeNewswire

    Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults

    Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults Study conducted in the United-States aims to.

  • GlobeNewswire

    Inventiva secures a new European patent strengthening and extending the protection of its lead product candidate lanifibranor

    Inventiva secures a new European patent strengthening and extending the protection of its lead product candidate lanifibranor The latest European patent granted by the European.

  • GlobeNewswire

    Inventiva - New promising results on lanifibranor to be presented at The Liver Meeting® 2019

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that its abstract on the evaluation of lanifibranor in a pre-clinical model of cirrhosis has been selected by the American Association for the Study of Liver Diseases (AASLD) for an oral presentation at the upcoming The Liver Meeting® 2019 in Boston, Massachusetts, USA (November 8-12, 2019). The study, which was led by Prof. Jordi Gracia-Sancho1, aimed at evaluating lanifibranor in a pre-clinical model of cirrhosis.

  • Inventiva S.A. (EPA:IVA): Poised For Long-Term Success?
    Simply Wall St.

    Inventiva S.A. (EPA:IVA): Poised For Long-Term Success?

    The most recent earnings announcement Inventiva S.A.'s (EPA:IVA) released in April 2019 signalled that losses became...

  • GlobeNewswire

    Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the United States Patent and Trademark Office (USPTO) granted a new patent on August 20, 2019 that protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035. This new patent further strenghens Inventiva’s patent portfolio for lanifibranor, the Company’s lead product candidate, in the United States, which already comprised a New Chemical Entity (NCE) patent and a patent protecting the use of lanifibranor in several diseases including non-alcoholic steatohepatitis (“NASH”).

  • GlobeNewswire

    Inventiva - H1 2019 Financial Information and Corporate Business Update

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today reported its cash position as at June 30, 2019 and revenues for the first half of 2019, and provided a corporate business update.

  • GlobeNewswire

    Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.

  • GlobeNewswire

    Inventiva announces the creation of its Scientific Advisory Board

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the creation of its Scientific Advisory Board (SAB) to provide external scientific review and high-level advice to the Company’s management with regards to its R&D activities and product portfolio. The SAB will cover Inventiva’s key areas of research and development with a particular focus on non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS) and oncology. As such, it will support Inventiva’s management regarding the preclinical and clinical aspects of the Company’s development programs and its global scientific policy, including targets, fields of research, partnerships and market access.

  • GlobeNewswire

    Inventiva Announces End of Patient Recruitment for its Phase IIa Trial in the Treatment of MPS VI

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the end of patient recruitment for its Phase IIa iMProveS (improve MPS treatment) trial in Europe evaluating odiparcil for the treatment of mucopolysaccharidosis type VI (MPS VI).

  • GlobeNewswire

    Nawal Ouzren and Heinz Maeusli appointed to Inventiva’s Board of Directors

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the appointment of Nawal Ouzren and Heinz Maeusli as members of its Board of Directors following the Company’s Ordinary and Extraordinary Shareholders’ General Meeting on May 27, 2019.

  • What Kind Of Shareholder Appears On The Inventiva S.A.'s (EPA:IVA) Shareholder Register?
    Simply Wall St.

    What Kind Of Shareholder Appears On The Inventiva S.A.'s (EPA:IVA) Shareholder Register?

    The big shareholder groups in Inventiva S.A. (EPA:IVA) have power over the company. Institutions often own shares in...

  • GlobeNewswire

    Inventiva to Present at the Jefferies 2019 Healthcare Conference

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, will present a corporate overview, followed by a breakout session, at the upcoming Jefferies 2019 Healthcare Conference, being held on June 4-7, 2019, at the Grand Hyatt New York hotel in New York, USA.

  • GlobeNewswire

    Repeat: Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the U.S. Food and Drug Administration (FDA) has lifted for lanifibranor the clinical hold in place on the peroxisome proliferator-activated receptor (PPAR) target class. This decision enables Inventiva to conduct clinical trials equal to or longer than six months evaluating lanifibranor for the treatment of NASH.

  • GlobeNewswire

    Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the U.S. Food and Drug Administration (FDA) has lifted for lanifibranor the clinical hold in place on the peroxisome proliferator-activated receptor (PPAR) target class. This decision enables Inventiva to conduct clinical trials equal to or longer than six months evaluating lanifibranor for the treatment of NASH.

  • GlobeNewswire

    Q1 2019 Financial Information and Corporate Business Update

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today reported its cash position and revenues for the first quarter 2019, and provided a corporate business update. As at 31 March 2019, Inventiva’s cash and cash equivalents were €47.3 million, vs. €56.7 million on 31 December 2018, in line with the Company’s expectations. Inventiva’s cash burn was primarily driven by its ongoing preclinical and clinical studies.

  • GlobeNewswire

    Inventiva to present new results of its YAP-TEAD oncology program at the AACR Special Conference on The Hippo Pathway

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the abstract on the evaluation of its YAP-TEAD Protein-Protein Interaction inhibitors for treating Malignant Pleural Mesothelioma (MPM) submitted to the American Association for Cancer Research (AACR) has been accepted for a poster presentation at the upcoming AACR Special Conference on The Hippo Pathway: Signaling, Cancer, and Beyond (May 8-11, 2019, San Diego, California). The study, which aimed at supporting a multi-pronged approach to treat MPM, will be presented by Anne Soudé, Senior Scientist in charge of the YAP-TEAD program at Inventiva.

  • GlobeNewswire

    Inventiva to Participate at the H.C. Wainwright Global Life Sciences Conference

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, will present a corporate overview, followed by one-on-one meetings, at the upcoming H.C Wainwright Global Life Sciences Conference, being held on April 7-9, 2019, at the Grosvenor House in London.

  • What Are Analysts Saying About The Future Of Inventiva S.A.’s (EPA:IVA)?
    Simply Wall St.

    What Are Analysts Saying About The Future Of Inventiva S.A.’s (EPA:IVA)?

    Inventiva S.A.'s (EPA:IVA) announced its latest earnings update in December 2018, which showed company earnings became less negative compared to the previous year's level - great news for investors Below,Read More...

  • GlobeNewswire

    INVENTIVA to Present Corporate Overview at the Cowen and Company 39th Annual Health Care Conference

                                                    Inventiva to Present Corporate Overview at the Cowen and Company 39 th Annual Health Care Conference Daix (France), March 6, 2019 - Inventiva (Euronext: ...

  • GlobeNewswire

    INVENTIVA : The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation (RPDD) to odiparcil, the Company`s product candidate in development for the treatment of mucopolysaccharidosis (MPS) VI, a type of rare, progressive genetic disorder characterized by a deficiency in the lysosomal enzymes responsible for the normal degradation of glycosaminoglycans (GAGs). The designation of rare pediatric disease status confirms odiparcil`s eligibility to receive a Priority Review Voucher upon FDA approval of a new drug application (NDA) to be filed for odiparcil for the treatment of MPS VI.

  • GlobeNewswire

    INVENTIVA: 2018 Full-Year Results : Important Progress in R&D Portfolio and Solid Cash Position

    2018 Full-Year Results : Important Progress in R&D Portfolio and Solid Cash Position   Reinforcement of the clinical development of lanifibranor for the treatment of NASH with the extension of the Phase ...

  • GlobeNewswire

    Invitation - Inventiva's Full Year 2018 Financial Results publication

    INVITATION Inventiva`s Full Year 2018 Financial Results publication Wednesday, February 27, 2019 Inventiva`s full year 2018 financial results will be released at 5:45 pm (Paris), 4:45 pm (London) . They ...

  • GlobeNewswire

    Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH

    Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the screening of the first patient in the United States for its Phase IIb NATIVE (NASH Trial to Validate IVA337 Efficacy) clinical trial evaluating lanifibranor, the Company`s lead product candidate, for the treatment of non-alcoholic steatohepatitis (NASH), a common and progressive chronic liver disease for which there is currently no approved therapy. Inventiva also announced that the NATIVE Data Safety Monitoring Board (DSMB) held its second meeting and recommended that the trial continue as planned.